CareDx, Inc. (CDNA) has been one of the more dramatic precision-medicine stories of the year, rallying from a 52-week low of $14.03 to a recent close near $67. With shares now sitting just below their 52-week high of $72.51, the question is whether the stock can push through to $74 — a level discussed on Wall Street but one that now implies only modest additional upside.
Because the stock has run so far, most analyst price targets now trail the current price, which means there is no usable consensus above the market. The $74 figure therefore reflects the highest and only credible current target above the price: BTIG analyst Mark Massaro raised his target to $74 from $60 on September 24, 2026, reiterating a Buy rating. For context, Canaccord Genuity initiated coverage with a Buy and a $65 target on September 1, 2026, while the broader range spans roughly $45 to $74, with the average near $58 to $62. BTIG's thesis is a valuation "multiple gap": CareDx trades near 5.1 times 2026 revenue estimates, versus about 12.9 times for specialty-lab peers and 15 to 19 times for oncology-diagnostics peers.
At a recent close near $67.08, CareDx carries a market value of roughly $3.5 billion and a trailing P/E (price-to-earnings ratio) around 32. Reaching $74 requires an advance of about 10%, which is a modest move by the standards of a stock with a five-year beta near 2.4. Still, $74 would mark a new all-time high, so the path depends on the market extending an already steep re-rating rather than merely consolidating.
The fundamentals have improved sharply. In July 2026, Medicare finalized a Local Coverage Determination (LCD), a coverage rule confirming reimbursement for CareDx's transplant-surveillance portfolio — AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung — effective August 30, 2026. Second-quarter revenue rose 52% year over year to $132 million, and adjusted net income tripled to $20 million, or $0.37 per share, beating estimates of $0.23. Management raised full-year revenue guidance to $490 million to $500 million and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) to $66 million to $78 million. The acquisition of Naveris adds oncology diagnostics, including MRD (minimal residual disease) testing, a market that could justify a richer valuation multiple.
Valuation is the central obstacle. The stock has more than quadrupled off its 52-week low and still trades above most analyst targets, suggesting a large share of the good news is already reflected in the price. The oncology pipeline — Naveris and the company's AlloHeme test — is early-stage and must still deliver. CareDx also remains dependent on its core AlloSure and HeartCare franchise, leaving it exposed to any future reimbursement or coverage changes, and it competes directly with Natera (NTRA), a larger diagnostics peer with its own transplant and oncology MRD offerings.
The 52-week high of $72.51 is the immediate resistance level; $74 represents a breakout to uncharted territory. On the downside, the round $60 level — near Canaccord's $65 target and BTIG's prior $60 target — is a logical support zone, with deeper support near $50 and the post-LCD surge close of $40.34. The long-term structure remains firmly bullish, but the proximity of the price to its record high makes the next leg more dependent on fresh catalysts than on momentum alone.
Analyst price targets generally reflect a roughly 12-month research horizon. The next items most relevant to the $74 objective are the company's third-quarter results — reported in early November 2026 — along with any guidance updates, progress integrating Naveris, oncology-pipeline milestones, and any new CMS or Medicare coverage developments. Additional analyst target revisions, in either direction, will signal whether the Street begins closing the valuation gap BTIG has highlighted.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a high-beta name like CareDx, where sentiment can shift quickly, these tools help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual screening. Explore the signals to see how the model is reading CDNA's current trend alongside the broader market.
The $74 target is a realistic but modest ask — roughly 10% above the recent price and only slightly above the 52-week high. It rests on a single, publicly discussed analyst objective rather than a consensus, because the broader analyst range of roughly $45 to $74 now trails the market price. Strong revenue growth, confirmed Medicare coverage, and an oncology expansion support the case, while a stretched valuation, an early-stage pipeline, and competition from Natera are the principal obstacles. Whether CDNA reaches $74 will likely hinge on continued execution, further multiple expansion, and whether more analysts raise their targets to reflect the company's new profile.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with ADPT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then ADPT could also see price increases.
| Ticker / NAME | Correlation To CDNA | 1D Price Change % | ||
|---|---|---|---|---|
| CDNA | 100% | +2.23% | ||
| ADPT - CDNA | 38% Loosely correlated | +3.73% | ||
| PSNL - CDNA | 37% Loosely correlated | -0.25% | ||
| CSTL - CDNA | 37% Loosely correlated | +3.68% | ||
| ABT - CDNA | 37% Loosely correlated | -1.89% | ||
| ILMN - CDNA | 35% Loosely correlated | +5.57% | ||
More | ||||